FIELD: biotechnology.
SUBSTANCE: disclosed is a method for determining activity of an immune cell, which involves the steps of bringing an immune cell into contact with an effective amount of a stimulant, for example, phytohemagglutinin (PHA) and determining the amount of cytokine produced by the immune cell. Also described are a kit for determining activity of immune cells and methods of using active immune cells as immunotherapeutic treatment.
EFFECT: invention is used to treat cancer.
14 cl, 10 dwg, 1 ex
Title | Year | Author | Number |
---|---|---|---|
METHODS FOR IMMUNOTHERAPY WITH CHIMERIC ANTIGEN RECEPTOR IN COMBINATION WITH 4-1BB AGONIST | 2019 |
|
RU2788524C2 |
CHIMERIC ANTIGEN RECEPTORS WITH MUTATED CD28 COSTIMULATION DOMAINS | 2018 |
|
RU2800922C2 |
UNIVERSAL ANTIGEN PRESENTING CELLS AND THEIR USE | 2019 |
|
RU2809113C2 |
METHODS OF EX VIVO EXPANSION OF NATURAL KILLER CELLS AND THEIR USE | 2019 |
|
RU2814083C2 |
METHOD FOR MALIGNANT TUMOUR DIAGNOSTICS AND DIAGNOSTIC KIT BY NK-CELLS ACTIVITY MEASUREMENT | 2012 |
|
RU2635194C2 |
COVALENTLY CLOSED NON-CODING IMMUNOMODULATORY DNA CONSTRUCT | 2015 |
|
RU2668387C2 |
METHOD FOR ASSESSING THE SENSITIVITY OF A TUMOR TO IMMUNO-ONCOLOGICAL DRUGS | 2021 |
|
RU2771760C1 |
CANCER TREATMENT WITH CHIMERIC CD33 ANTIGEN RECEPTOR | 2015 |
|
RU2747384C2 |
COMPOSITIONS AND METHODS OF IMMUNOTHERAPY | 2014 |
|
RU2680010C2 |
COMPOSITIONS AND METHODS FOR IMMUNOTHERAPY | 2013 |
|
RU2729401C2 |
Authors
Dates
2024-07-08—Published
2020-02-14—Filed